mRNA/LNP Manufacturing: From Pandemic Platform to Industrial Discipline

After the urgent push and approval of mRNA vaccines for COVID-19, more people are thinking of the utility of the space for non-viral gene delivery in general. mRNA technology did not begin with COVID-19, and it did not end with it. The pandemic accelerated investment on an unprecedented scale, and by the time it began to fade, practitioners were writing about mRNA-LNP manufacturing as an established industrial discipline. 

mRNA vaccines and treatment open the door for quick and flexible approvals/ developments due to the flexible design of mRNA and higher accuracy compared to other forms of gene targeted therapy. A process void of cells, mitigates concerns of pathogens or related microorganisms, risk of transmission of infectious agents compared to traditional vaccine manufacture involving pathogen propagation, and risk of residual live viruses in the product - all of which are part of CMC in other gene editing or antigen treatments.

LNPs are a mode of transport for the mRNA into the cell of interest; protecting mRNA from degradation while facilitating its specific cellular uptake and endosome escape. With complexity of mRNA processes plus the LNPs, CMC is crucial and expertise important for manufacturers. CDMOs are building integrated end-to-end GMP capabilities, and the April 2026 LNP Formulation and Process Development Summit confirmed that the scientific foundation is established. 

The CMC challenges are specific – ie LNP size and morphology control are directly linked to potency and in vivo performance, delivery related to particle engineering and characterization, storage stability, etc.

For early-stage programs, deferring the manufacturing conversation for later phases carries  risk. With regulatory expectations rising, and FDA/ ICH guidance defining more aspects of what comparability, potency, and process control look like at commercial scale, formulation decisions made in early phase can impact far into the future.

At Pharmefex, we support mRNA and LNP programs across the all CMC stages of life: analytical method development, formulation strategy, CDMO selection and governance, IND authoring, and regulatory preparation through first-in-human. We have experts ready to help guide, problem solve and support. The complexity of this platform is well understood. What determines how smoothly a program progresses is how early that understanding is applied.

Sources

1. Kalghatgi, S. PhD — mRNA-LNP Vaccine Manufacturing: An In-Depth Examination (LinkedIn, 2023)

https://www.linkedin.com/pulse/mrna-lnp-vaccine-manufacturing-in-depth-examination-kalghatgi-phd

2. LNP Formulation & Process Development Summit 2026

https://lnp-formulation-process-development-pharma.com/

#mRNA #LNP #CMC #Biotech #Pharma #DrugDevelopment #NonViralDelivery #Manufacturing #RegulatoryStrategy #Pharmefex